Feature | December 06, 2013

Stroke Mortality is Down, but the Reason Remains a Mystery

stroke treatment devices clinical trial study alabama
December 6, 2013 — A national group of leading scientists, including one University of Alabama at Birmingham (UAB) expert, said that for more than 100 years, fewer people have been dying of stroke, yet it is still unclear why this decline remains constant.
 
The American Heart Assn. (AHA) and American Stroke Assn. have published a scientific statement, “Factors Influencing the Decline in Stroke Mortality,” which has also been affirmed by the American Academy of Neurology as an educational tool for neurologists. The statement is published in the AHA journal Stroke.
 
Stroke is a leading cause of long-term disability and was previously recognized as the third leading cause of death in the United States, according to the National Stroke Association. However, stroke has now fallen to the fourth leading cause of death due to decreases in people dying from it. This has led the Centers for Disease Control and Prevention to acknowledge the decline and a similar decline in heart disease as one of the 10 great achievements in public health of the 20th century.
 
George Howard, Dr.P.H., professor, department of Biostatistics, School of Public Health, UAB, and statement co-author explained that, even with these dramatic decreases, there is still more to be done.
 
“Stroke has been declining since 1900, and this could be a result of changes leading to fewer people having a stroke or because people are less likely to die after they have a stroke,” said Howard. “Nobody really knows why, but several things seem to be contributing to fewer deaths from stroke.”
 
Perhaps the biggest contributor to the decline, Howard said, are changes leading to lower blood pressure levels, which is the biggest of the stroke risk factors. Other contributors may include reductions in smoking, better treatment of cholesterol and how people are cared for after having a stroke.
 
“We don’t know how much all of the sources are contributing,” said Howard. “Certainly, we want it to keep going down; but if we don’t understand why the numbers are decreasing, we can’t work toward that trend.”
 
Howard said that, in the last 11 years, stroke deaths have declined by 30 percent.
 
“It’s a big deal, so you could argue that our battle is won,” he said. “But I think we still have a lot to be accomplished in this area.”
 
Andrei Alexandrov, M.D., professor of neurology and director, UAB Comprehensive Stroke Center, was not affiliated with the statement but said it brings welcome news.
 
“This likely is attributable not only to better arterial blood pressure control over recent years, but also to a greater number of neurological specialists focused on stroke care across many hospitals in the United States and abroad,” said Alexandrov. “Better early stroke recognition and specialized care can also reduce the risk of dying from stroke.”
 
Alexandrov pointed out one finding of the statement — the lower death rate among adults younger than 65 years of age — deserves further attention since a large proportion of stroke victims in the Southeastern United States are young.
 
“More efforts are needed to reduce mortality and prevent first-ever stroke incidence, as well as to reverse disability following stroke by improving patient access to hospitals providing clot-busting therapy,” said Alexandrov.
 
Howard agrees that, while stroke prevention and care have played a large part in the decline of stroke mortality, more research needs to be done in stroke prevention.
 
“This brings up an interesting question: should more research resources go toward areas where we’ve seen success, or should they go where differences haven’t been made yet?” said Howard. “I’d say there’s an argument for both.”
 
For more information: www.uab.edu

Related Content

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

News | Cardiovascular Clinical Studies | July 22, 2020
July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to re
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp